Results 101 to 110 of about 176,622 (333)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors [PDF]

, 2021
Christian U. Blank, Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene‐Tchaleu, Jing Zhu, Yun Han, Edward Cha, Mario Sznol   +9 more
openalex   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Salvage Fractionated Stereotactic Re-irradiation (FSRT) for Patients with Recurrent High Grade Gliomas Progressed after Bevacizumab Treatment [PDF]

, 2017
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the manage- ment of high grade gliomas (HGG), with a median overall survival of less than 4 months (m).
Andrews MD, David W., Bar-Ad, Voichita, Bhamidipati, Deepak, Blomain, Erik S, Dan, Tu, Evans, James J., Farrell, MD, Christopher J, Glass, MD, Jon, Judy, MD, Kevin, Kim, Lyndon, Palmer, Joshua, Shi, Wenyin, Siglin, Joshua, Wang, Yang, Werner-Wasik, Maria   +14 more
core   +2 more sources

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

, 2021
Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Reyes Bernabé, Linda Coate, Mariano Provencio, Rosario García Campelo, Sinéad Cuffe, Sayed M.S. Hashemi, Martin Früh, Bartomeu Massutí, José García-Sánchez, Manuel Dómine, Margarita Majem, J.M. Sánchez-Torres, Christian Britschgi, Miklos Pless, Georgia Dimopoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, Rafael Rosell, Rolf A. Stahel, Solange Peters, Rolf A. Stahel, Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Reyes Bernabé, Mariano Provencio, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho   +99 more
openalex   +2 more sources

Image analysis method for measurement and prediction of intra‐matrix IgG diffusion

Biotechnology Progress, EarlyView.
Experimental and image analysis workflow for b‐IgG diffusion in hyaluronic acid (HA) matrix. Abstract Measurement and imaging of intra‐matrix protein therapeutics diffusion is important due to the emergence of injectable biologics currently in various stages of research and clinical testing.
Riya Debbarma, Antonio C. F. dos Santos, Michael Ladisch   +2 more
wiley   +1 more source

Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer

Cancer Treatment and Research Communications
Purpose: Data from the CT-P16 3.1 study demonstrated equivalent efficacy between CT-P16, a bevacizumab biosimilar, and European-approved reference bevacizumab (EU-bevacizumab) for the primary endpoint of objective response rate (ORR) during induction ...
Zoran Andric, Fedor Moiseenko, Tamta Makharadze, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Hana Ju, Eric Hyungseok Baek, Soonbum Kwon, IlSung Chang, SinHye Kim, HyunAh Kim, EunKyung Lee, Claire Verschraegen   +15 more
doaj   +1 more source

Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness. [PDF]

CA Cancer J Clin
CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Campos SM, DiSilvestro J, Blank SV.
europepmc   +2 more sources

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer [PDF]

, 2020
Junsik Park, Kyung Jin Eoh, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Jung‐Yun Lee   +6 more
openalex   +1 more source

Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non‐small cell lung cancer: a prospective phase II study (GASTO‐1053)

Cancer Communications, EarlyView.
Abstract Background The prognosis for non‐small cell lung cancer (NSCLC) patients with extensive brain metastases (BMs) treated with radiotherapy alone remains poor. Based on the synergistic potential of radiotherapy and angiogenesis inhibitors, we initiated this phase II study to assess the efficacy and safety of combining bevacizumab (Bev) with ...
Rui Zhou, Shiyang Zheng, Daquan Wang, Fang Dong, Hongmei Zhang, Tao Zhang, Qiaoting Luo, Biaoshui Liu, Hui Liu, Jun Zhang, Fangjie Liu, Bin Wang, Likun Chen, Yonggao Mou, Kangqiang Peng, Bo Qiu, Hui Liu   +16 more
wiley   +1 more source